- Home
- OKUR vs CLLS Comparison
OKUR vs CLLS Comparison
Compare OKUR & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OKUR
- CLLS
- Stock Information
- Founded
- OKUR 2011
- CLLS 1999
- Country
- OKUR United States
- CLLS France
- Employees
- OKUR N/A
- CLLS N/A
- Industry
- OKUR
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- OKUR
- CLLS Health Care
- Exchange
- OKUR NYSE
- CLLS Nasdaq
- Market Cap
- OKUR 234.2M
- CLLS 240.2M
- IPO Year
- OKUR N/A
- CLLS 2007
- Fundamental
- Price
- OKUR $18.26
- CLLS $1.80
- Analyst Decision
- OKUR Strong Buy
- CLLS Buy
- Analyst Count
- OKUR 2
- CLLS 2
- Target Price
- OKUR $37.50
- CLLS $8.00
- AVG Volume (30 Days)
- OKUR 74.5K
- CLLS 29.1K
- Earning Date
- OKUR 11-14-2024
- CLLS 11-04-2024
- Dividend Yield
- OKUR N/A
- CLLS N/A
- EPS Growth
- OKUR N/A
- CLLS N/A
- EPS
- OKUR N/A
- CLLS N/A
- Revenue
- OKUR N/A
- CLLS $19,635,000.00
- Revenue This Year
- OKUR N/A
- CLLS $271.02
- Revenue Next Year
- OKUR N/A
- CLLS $33.48
- P/E Ratio
- OKUR N/A
- CLLS N/A
- Revenue Growth
- OKUR N/A
- CLLS N/A
- 52 Week Low
- OKUR $9.80
- CLLS $0.96
- 52 Week High
- OKUR $82.90
- CLLS $3.77
- Technical
- Relative Strength Index (RSI)
- OKUR N/A
- CLLS 30.02
- Support Level
- OKUR N/A
- CLLS $1.78
- Resistance Level
- OKUR N/A
- CLLS $1.96
- Average True Range (ATR)
- OKUR 0.00
- CLLS 0.09
- MACD
- OKUR 0.00
- CLLS -0.01
- Stochastic Oscillator
- OKUR 0.00
- CLLS 6.90
About OKUR ONKURE THERAPEUTICS INC
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. It has a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.